Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Distinguished Unit Citations: 15 Medal of Honor: 4 Private John R. Towle(KIA) Private First Class Charles N. Deglopper(KIA) First Sergeant Leonard A. Funk Jr. Private Joe Gandara(KIA) (issued 18 March 2014) Distinguished Service Cross: 37 Distinguished Service Medal: 2 Silver Star: 898 Legion of Merit: 29 Soldier's Medal: 49 Bronze Star Medal: 1,894 Air Medal: 15
In static solution culture, plants are grown in containers of nutrient solution, such as glass Mason jars (typically, in-home applications), pots, buckets, tubs, or tanks. The solution is usually gently aerated but may be un-aerated. If un-aerated, the solution level is kept low enough that enough roots are above the solution so they get adequate oxygen. A hole is cut (or drilled) in the top of the reservoir for each plant; if it is a jar or tub, it may be its lid, but otherwise, cardboard, foil, paper, wood or metal may be put on top. A single reservoir can be dedicated to a single plant, or to various plants. Reservoir size can be increased as plant size increases. A home-made system can be constructed from food containers or glass canning jars with aeration provided by an aquarium pump, aquarium airline tubing, aquarium valves or even a biofilm of green algae on the glass, through photosynthesis. Clear containers can also be covered with aluminium foil, butcher paper, black plastic, or other material to eliminate the effects of negative phototropism. The nutrient solution is changed either on a schedule, such as once per week, or when the concentration drops below a certain level as determined with an electrical conductivity meter. Whenever the solution is depleted below a certain level, either water or fresh nutrient solution is added. A Mariotte's bottle, or a float valve, can be used to automatically maintain the solution level. In raft solution culture, plants are placed in a sheet of buoyant plastic that is floated on the surface of the nutrient solution.
The Peptide Transporter Carbon Starvation (CstA) Family (TC# 2.A.114) is a member of the APC superfamily and consists of proteins from bacteria and archaea. These proteins are of various sizes and topologies. For example, CstA of E. coli has 701 aas with 18 putative TMSs. It has a long N-terminal CstA domain and a short C-terminal DUF4161 domain. This protein is encoded by a carbon starvation inducible gene, cstA, that is under cyclic AMP-CRP control. Circumstantial evidence suggested that it may be a peptide transporter. A Campylobacter jejuni homologue has been shown to transport di- and tripeptides (see TC# 2.A.114.1.5). Proteins currently known to belong to the CstA family are listed in the Transporter Classification Database. As of early 2016, there is no crystal structural data available for members of the CstA family on RCSB.
Sources: en.wikipedia.org
Nearly all of our knowledge of Paleolithic people and way of life comes from archaeology and ethnographic comparisons to modern hunter-gatherer cultures such as the !Kung San who live similarly to their Paleolithic predecessors. The economy of a typical Paleolithic society was a hunter-gatherer economy. Humans hunted wild animals for meat and gathered food, firewood, and materials for their tools, clothes, or shelters. The population density was very low, around only 0.4 inhabitants per square kilometre (1/sq mi). This was most likely due to low body fat, infanticide, high levels of physical activity among women, late weaning of infants, and a nomadic lifestyle. In addition, even a large area of land could not support many people without being actively farmed – food was difficult to come by and so groups were prevented from growing too large by the amount of food they could gather. Like contemporary hunter-gatherers, Paleolithic humans enjoyed an abundance of leisure time unparalleled in both Neolithic farming societies and modern industrial societies. At the end of the Paleolithic, specifically the Middle or Upper Paleolithic, people began to produce works of art such as cave paintings, rock art and jewellery and began to engage in religious behavior such as burials and rituals.
After harnessing fire, humans discovered other forms of energy. The earliest known use of wind power is the sailing ship; the earliest record of a ship under sail is that of a Nile boat dating to around 7,000 BCE. From prehistoric times, Egyptians likely used the power of the annual flooding of the Nile to irrigate their lands, gradually learning to regulate much of it through purposely built irrigation channels and "catch" basins. The ancient Sumerians in Mesopotamia used a complex system of canals and levees to divert water from the Tigris and Euphrates rivers for irrigation. Archaeologists estimate that the wheel was invented independently and concurrently in Mesopotamia (in present-day Iraq), the Northern Caucasus (Maykop culture), and Central Europe. Time estimates range from 5,500 to 3,000 BCE, with most experts putting it closer to 4,000 BCE. The oldest artifacts with drawings depicting wheeled carts date from about 3,500 BCE. More recently, the oldest-known wooden wheel in the world as of 2024 was found in the Ljubljana Marsh of Slovenia; Austrian experts have established that the wheel is between 5,100 and 5,350 years old. The invention of the wheel revolutionized trade and war. It did not take long to discover that wheeled wagons could be used to carry heavy loads. The ancient Sumerians used a potter's wheel and may have invented it. A stone pottery wheel found in the city-state of Ur dates to around 3,429 BCE, and even older fragments of wheel-thrown pottery have been found in the same area.
Arab immigration to Venezuela started as early as the 19th and 20th centuries, with migrants primarily hailing from the Ottoman provinces of Lebanon, Syria, and Palestine. They settled predominantly in Caracas, and have significantly influenced Venezuelan culture, particularly in terms of Arabic food and music. Religiously, the Arab-Venezuelans community consists mainly of Druze and Christians, who are affiliated with the Roman Catholic, Eastern Orthodox and Eastern Rite Catholic Churches. Venezuela hosts the largest Druze communities outside the Middle East, estimated at around 60,000 individuals. Most of them trace their ancestry back to Lebanon and Syria. More than 200,000 people from the As-Suwayda area hold Venezuelan citizenship, the majority of whom belong to the Syria's Druze sect and immigrated to Venezuela in the past century. The early Druze migrants to Venezuela assimilated well into the local population, with some even converting Catholicism. Nevertheless, many retained a strong Druze and Arab identity, along with adherence to Druze values. A prominent example of Druze influence in this Catholic country is the former vice president, Tareck El Aissami, who is of Druze descent. Other notable Venezuelan figures of Druze origin include Haifa El Aissami and Tarek William Saab.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.